Palbociclib Demonstrates Intracranial Activity in Progressive Brain Metastases Harboring Cyclin-dependent Kinase Pathway Alterations

Overview

Journal Nat Cancer

Specialty Oncology

Date 2022 Feb 5

PMID 35122016

Authors

Priscilla K Brastianos

Albert E Kim

Nancy Wang

Eudocia Q Lee

Jennifer Ligibel

Justine V Cohen

Ugonma N Chukwueke

Maura Mahar

Kevin Oh

Michael D White

Helen A Shih

Deborah Forst

Justin F Gainor

Rebecca S Heist

Elizabeth R Gerstner

Tracy T Batchelor

Donald Lawrence

David P Ryan

A John Iafrate

Anita Giobbie-Hurder

Sandro Santagata

Scott L Carter

Daniel P Cahill

Ryan J Sullivan

Affiliations

Soon will be listed here.

Abstract

Recent studies suggest that the cyclin-dependent kinase (CDK) pathway may be a therapeutic target for brain metastases (BM). Here, we present interim analysis of a basket trial evaluating the intracranial efficacy of the CDK inhibitor palbociclib in patients with progressive BM and CDK alterations. Our study met its primary endpoint and provides evidence for performing molecular testing of archival BM tissue, if available, to inform the choice of CNS-penetrant targeted therapy.

Citing Articles

Cancer brain metastasis: molecular mechanisms and therapeutic strategies.

Lu Y, Huang Y, Zhu C, Li Z, Zhang B, Sheng H Mol Biomed. 2025; 6(1):12.

PMID: 39998776 PMC: 11861501. DOI: 10.1186/s43556-025-00251-0.

Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition.

Yuzhalin A, Lowery F, Saito Y, Yuan X, Yao J, Duan Y Nat Cell Biol. 2024; 26(10):1773-1789.

PMID: 39304713 PMC: 11676029. DOI: 10.1038/s41556-024-01509-5.

Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.

Wilcox J, Chukwueke U, Ahn M, Aizer A, Bale T, Brandsma D Neuro Oncol. 2024; 26(10):1781-1804.

PMID: 38902944 PMC: 11449070. DOI: 10.1093/neuonc/noae103.

Combination of Palbociclib and Endocrine Therapy in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With or Without Brain Metastases.

Zhang Q, Lan X, Huang J, Xie X, Chen L, Song L Technol Cancer Res Treat. 2024; 23:15330338231206986.

PMID: 38233376 PMC: 10798105. DOI: 10.1177/15330338231206986.

CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis.

Nayyar N, de Sauvage M, Chuprin J, Sullivan E, Singh M, Torrini C Clin Cancer Res. 2023; 30(2):420-435.

PMID: 37611074 PMC: 10872577. DOI: 10.1158/1078-0432.CCR-23-0433.

References

Adkins D, Ley J, Neupane P, Worden F, Sacco A, Palka K . Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial. Lancet Oncol. 2019; 20(9):1295-1305. DOI: 10.1016/S1470-2045(19)30405-X. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Brastianos P, Carter S, Santagata S, Cahill D, Taylor-Weiner A, Jones R . Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015; 5(11):1164-1177. PMC: 4916970. DOI: 10.1158/2159-8290.CD-15-0369. View

Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T . Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-51. DOI: 10.1016/s0360-3016(96)00619-0. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

Davies M, Saiag P, Robert C, Grob J, Flaherty K, Arance A . Dabrafenib plus trametinib in patients with BRAF-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017; 18(7):863-873. PMC: 5991615. DOI: 10.1016/S1470-2045(17)30429-1. View

McClendon A, Dean J, Rivadeneira D, Yu J, Reed C, Gao E . CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012; 11(14):2747-55. PMC: 3409014. DOI: 10.4161/cc.21127. View

Wu Y, Ahn M, Garassino M, Han J, Katakami N, Kim H . CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). J Clin Oncol. 2018; 36(26):2702-2709. DOI: 10.1200/JCO.2018.77.9363. View

Shih D, Nayyar N, Bihun I, Dagogo-Jack I, Gill C, Aquilanti E . Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nat Genet. 2020; 52(4):371-377. PMC: 7136154. DOI: 10.1038/s41588-020-0592-7. View

10.

Goldberg S, Gettinger S, Mahajan A, Chiang A, Herbst R, Sznol M . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17(7):976-983. PMC: 5526047. DOI: 10.1016/S1470-2045(16)30053-5. View

11.

Tawbi H, Forsyth P, Algazi A, Hamid O, Hodi F, Moschos S . Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. N Engl J Med. 2018; 379(8):722-730. PMC: 8011001. DOI: 10.1056/NEJMoa1805453. View

12.

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

13.

Gao J, Cheng J, Bloomquist E, Sanchez J, Wedam S, Singh H . CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis. Lancet Oncol. 2019; 21(2):250-260. DOI: 10.1016/S1470-2045(19)30804-6. View

14.

Canavese M, Santo L, Raje N . Cyclin dependent kinases in cancer: potential for therapeutic intervention. Cancer Biol Ther. 2012; 13(7):451-7. DOI: 10.4161/cbt.19589. View

15.

Knudsen E, Witkiewicz A . The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017; 3(1):39-55. PMC: 5347397. DOI: 10.1016/j.trecan.2016.11.006. View

16.

Brastianos P, Curry W, Oh K . Clinical discussion and review of the management of brain metastases. J Natl Compr Canc Netw. 2013; 11(9):1153-64. DOI: 10.6004/jnccn.2013.0133. View

17.

Cristofanilli M, Turner N, Bondarenko I, Ro J, Im S, Masuda N . Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre,.... Lancet Oncol. 2016; 17(4):425-439. DOI: 10.1016/S1470-2045(15)00613-0. View

18.

Michaud K, Solomon D, Oermann E, Kim J, Zhong W, Prados M . Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 2010; 70(8):3228-38. PMC: 2855904. DOI: 10.1158/0008-5472.CAN-09-4559. View

19.

Shapiro G . Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006; 24(11):1770-83. DOI: 10.1200/JCO.2005.03.7689. View

20.

Lin N, Lee E, Aoyama H, Barani I, Barboriak D, Baumert B . Response assessment criteria for brain metastases: proposal from the RANO group. Lancet Oncol. 2015; 16(6):e270-8. DOI: 10.1016/S1470-2045(15)70057-4. View